1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Esclerosis Múltiple

Esclerosis Múltiple

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • González-Gay MÁ, Gómez-Bernal F, Quevedo-Abeledo JC, Tejera-Segura B, Gómez-Moreno C, García-Barrera E, Villar LM, Ocejo-Vinyals JG, Largo R, Ferraz-Amaro I.

    Interleukin-2 is associated with cytopenias in systemic lupus erythematosus.

    AUTOIMMUNITY . 59(1): 2701071-2701071.

    [doi:10.1080/08916934.2026.2701071]

  • Ferraz-Amaro I, Quevedo-Abeledo JC, Tejera-Segura B, García-Barrera E, Villar LM, Ocejo-Vinyals JG, Largo R, González-Gay MÁ.

    Ultrasensitive quantification of serum IL-5 in systemic lupus erythematosus does not reveal utility as a biomarker for disease activity or damage.

    Journal of Translational Autoimmunity . 13: 100402-100402.

    [doi:10.1016/j.jtauto.2026.100402]

  • Cooney LA, Lim N, Harris KM, Smilek DE, Bathala P, Stengelin M, Sigal G, Wohlstadter JN, Cencioni MT, Fernández Velasco JI, Mao-Draayer Y, Fox DA, Griffith LM, Nash R, Villar LM, Muraro PA.

    Autologous Hematopoietic Transplantation Reduces Brain Inflammatory and Axoglial Damage Biomarkers in Multiple Sclerosis.

    Neurology-Neuroimmunology & Neuroinflammation . 13(6): .

    [doi:10.1212/NXI.0000000000200653]

  • Oreja-Guevara C, García Domínguez JM, Montero Escribano P, Costa-Frossard L, Martínez Ginés ML, Llaneza González MÁ, Prieto González JM, Ramo-Tello C, Alonso Torres AM, Calles C, Pérez Miralles F, Eichau S, Castillo-Triviño T, Belén Caminero A.

    Espasticidad en Esclerosis Múltiple: Recomendaciones para su Evaluación y Manejo Clínico en 2026.

    REVISTA DE NEUROLOGIA . 81(10): 51172-51172.

    [doi:10.31083/RN51172]

  • Rodríguez-García M, Gómez-Bernal F, Quevedo-Abeledo JC, Tejera-Segura B, García-Barrera E, Villar LM, Ocejo-Vinyals JG, Largo R, González-Gay MÁ, Ferraz-Amaro I.

    Ultrasensitive quantification links higher serum interferon-a and interferon-? levels with lower leukocyte and lymphocyte counts in lupus.

    RHEUMATOLOGY . 65(10): .

    [doi:10.1093/rheumatology/keag529]

  • Ferraz-Amaro I, Quevedo-Abeledo JC, Tejera Segura B, García-Barrera E, Villar LM, Ocejo-Vinyals JG, Largo R, Gonzalez-Gay MÁ.

    Interleukin-22 reflects adverse cardiometabolic features in SLE.

    Lupus Science & Medicine . 13(2): .

    [doi:10.1136/lupus-2026-002217]

  • Cobo-Calvo A, Cuello JP, Monreal E, Villacieros-Álvarez J, Díaz-Troyano N, Otero S, Tur C, García Domínguez JM, Costa-Frossard L, Sainz de la Maza S, Carvajal R, De Miguel Sánchez CJ, Goicochea-Briceño H, Arrambide G, Martínez-Gines ML, Castillo M, Fernández Velasco JI, Vilaseca A, Vidal-Jordana A, Ariño H, Bollo L, Higueras Y, Castilló J, Galán I, Midaglia L, Mongay-Ochoa N, Pappolla A, Río J, Rodríguez-Acevedo B, Zabalza A, Sastre-Garriga J, Meldaña Rivera A, Ruíz-Pérez I, De León-Luis J, Ortega Abad V, Villarrubia N, Rodero-Romero A, Gómez Lozano A, Arribas I, García AM, Comabella M, Rovira Á, Reimundo P, Carbonell M, Herrero J, Carreras E, Montalban X, Ferrer R, Villar ML, Tintore M.

    Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . 97(10): 859-868.

    [doi:10.1136/jnnp-2026-338790]

  • Ferraz-Amaro I, Quevedo-Abeledo JC, Tejera-Segura B, García-Barrera E, Villar LM, Ocejo-Vinyals JG, Largo R, González-Gay MÁ.

    Ultrasensitive serum levels of interleukin 13 in systemic lupus erythematosus patients: a cross-sectional study.

    BMC Rheumatology . 10(1): .

    [doi:10.1186/s41927-026-00694-0]

  • Veiga-González JL, Monreal E, Espiño M, Chico-García JL, Fernández-Velasco JI, Rodríguez-Jorge F, Villarrubia N, Rodero-Romero A, Sainz de la Maza S, Masjuan J, Costa-Frossard L, Villar LM.

    Kappa index: real-world study for assessing cut-off values that provide the best accuracy for multiple sclerosis diagnosis in patients with CIS.

    Frontiers in Immunology . 17: 1771566-1771566.

    [doi:10.3389/fimmu.2026.1771566]

  • Rodríguez-García M, Gómez-Bernal F, Quevedo-Abeledo JC, Tejera-Segura B, García-Barrera E, Villar LM, Ocejo-Vinyals JG, Mota-Pérez N, Largo R, González-Gay MÁ, Ferraz-Amaro I.

    Ultrasensitive serum interferon alpha equals interferon signatures as a marker of lupus disease activity.

    iScience . 29(8): 117137-117137.

    [doi:10.1016/j.isci.2026.117137]

  • Díez-Cirarda M, Matías-Guiu JA, Ruiz-Ortiz M, Aladro Y, Cuevas C, Domingo-Santos Á, Galán Sánchez-Seco V, Labiano-Fontcuberta A, Gómez-López A, Salgado-Cámara P, Costa-Frossard L, Monreal E, Sainz de la Maza S, Matías-Guiu J, Gil-Martínez L, Yus-Fuertes M, Montero-Escribano P, Martínez-Ginés ML, Ayuso-Peralta L, Melero H, Malpica N, Benito-León J.

    Ventral attention network connectivity differentiates radiologically isolated syndrome from multiple sclerosis: a longitudinal resting-state fMRI study.

    AMERICAN JOURNAL OF NEURORADIOLOGY . 47(8): 2163-2171. Nº de citas: 1

    [doi:10.3174/ajnr.A9212]

  • Cabañas Engenios G, Mena García N, Garay Albízuri P, Llanes Ferrer A, Sánchez Asensio A, Romero Ferro J, Gil Martinez L, Campos Jiménez M, Pastor González R, Rodríguez Jorge F, Sainz de la Maza S, Monreal Laguillo E, Villar LM, Masjuan Vallejo J, Costa-Frossard L, Chico García JL.

    Discontinuation of disease-modifying therapies in patients with multiple sclerosis: A retrospective case-control study.

    Multiple Sclerosis and Related Disorders . 112: 107343-107343.

    [doi:10.1016/j.msard.2026.107343]

  • Rodríguez-García M, Gómez-Bernal F, Quevedo-Abeledo JC, Tejera-Segura B, García-Barrera E, Villar LM, Ocejo-Vinyals JG, Mota-Pérez N, Llorca J, Largo R, González-Gay MÁ, Ferraz-Amaro I.

    Defining the optimal interferon-stimulated genes panel to reflect serum interferon-a levels in patients with systemic lupus erythematosus.

    BMC Medicine . 24(1): .

    [doi:10.1186/s12916-026-05102-5]

  • Martin-Moro F, Alcoceba M, Romero S, Marquet-Palomanes J, Alonso-Castronuño D, Astibia-Mahillo B, Andreu R, Perez-Alonso R, Rodriguez-Martin E, De Ramon C, Solano I, Martin Garcia-Sancho A, Piris-Villaespesa M, Blanco O, Roldan-Santiago E, Garcia-Marco JA, Subira D, Navarro-Bailon A, Garcia-Cosio M, Garcia-Vela JA, Lopez-Jimenez J.

    Phenotypic Characterization of Richter Transformation and De Novo Diffuse Large B-Cell Lymphoma With or Without Monoclonal B-Cell Lymphocytosis.

    MODERN PATHOLOGY . 39(7): 101009-101009.

    [doi:10.1016/j.modpat.2026.101009]

  • Macia-Villa C, Fernandez-Velasco JI, Ferre-Sanfrancisco M, Mendoza-Bravo DA, Ruiz-Bejerano AM, Ferrez-Hernandez C, Morell-Hita JL.

    Exploring the phenotypic expression of HLA-B27 in psoriatic arthritis.

    CLINICAL RHEUMATOLOGY . 45(6): 3399-3404.

    [doi:10.1007/s10067-026-08144-5]

  • Costa-Frossard L, Brieva L, García-Estévez DA, Martín-Martínez JM, Álvarez-Bravo G, Blasco-Quílez MR, Meca-Lallana JE, Calles-Hernández MC, Ramo Tello C, Muñoz-Fernández C, Barbero DE, López-Muñoz P, Prieto González JM, Candeliere-Merlicco A, Carmona O, Riancho J, Sola-Valls N, Carcelén-Gadea M, Borrega L, Gascón-Giménez F, Vilanova D, Pérez X, Villar LM.

    Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 27(11): .

    [doi:10.3390/ijms27114933]

  • Muñoz-Gómez S, Pariente-Rodríguez R, Chico-García JL, García de la Torre I, Navarro Caspistegui J, García-Domínguez JM, Schiaffino MT, Sánchez-Mateos P.

    Clinical and laboratory findings in patients with anti-myelin oligodendrocyte glycoprotein antibodies: experience from two tertiary hospitals in Madrid.

    Frontiers in Immunology . 17: 1809873-1809873.

    [doi:10.3389/fimmu.2026.1809873]

  • Chico-Garcia JL, Morales de la Prida M, Boix Lago A, García-Domínguez JM, Sepúlveda M, Martínez-Hernández E, Guasp M, Fonseca E, Calvi A, Alba-Isasi MT, Albertí B, Cid J, Lozano M, Charry P, Rodríguez-Jorge F, Sainz-Amo R, Sainz de la Maza S, Monreal E, Villar LM, Masjuan J, Valero-López G, Millán-Pascual J, Cuello JP, Palacios M, Gifreu Fraixinó A, Martínez-Gins ML, Álvarez Bravo G, Meca-Lallana JE, Costa-Frossard L, Blanco Y, Cabrera-Maqueda JM, Saiz A, Llufriu S.

    Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study.

    Therapeutic Advances in Neurological Disorders . 19: . Nº de citas: 1

    [doi:10.1177/17562864261440665]